The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Abstract
Background Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel in patients with relapsed or refractory large B-cell lymphomas. Methods We did a seamless design study at 14 cancer centres in the USA. We enrolled adult patients (aged ≥18 years) with relapsed or refractory large B-cell lymphomas. Eligible histological subgroups included diffuse large B-cell lymphoma, high-grade B-cell lymphoma with rearrangements of MYC and either BCL2, BCL6, or both (double-hit or triple-hit lymphoma), diffuse large B-cell lymphoma transformed from any indolent lymphoma, primary mediastinal B-cell lymphoma, and follicular lymphoma grade 3B. Patients were assigned to one of three target dose levels of liso-cel as they were sequentially tested in the trial (50 × 10 6 CAR + T cells [one or two doses], 100 × 10 6 CAR + T cells, and 150 × 10 6 CAR + T cells), which were administered as a sequential infusion of two components (CD8 + and CD4 + CAR + T cells) at equal target doses. Primary endpoints were adverse events, dose-limiting toxicities, and the objective response rate (assessed per Lugano criteria); endpoints were assessed by an independent review committee in the efficacy-evaluable set (comprising all patients who had confirmed PET-positive disease and received at least one dose of liso-cel). This trial is registered with ClinicalTrials.gov, NCT02631044. Findings Between Jan…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, five CAR T cell products are approved for commercial use and available on the U.S. market, three for B-cell leukemia and lymphoma (tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel), one for mantle cell lymphoma (brexucabtagene autoleucel), and one for multiple myeloma (idecabtagene vicleucel) (2-8).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [3]
Citations
Cites
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationCheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Self-citationCurrent concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Self-citationOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,703
Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,625
Hay, K. A., Hanafi, L.-A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., et al. (2017) · Blood · doi:10.1182/blood-2017-06-793141 · Cited by 1,156
Self-citationTurtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016
Self-citation
Research works printed but not linked: 1
- DeAngelo, 2017, Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET study), J Immunother Cancer, 5, 116
Cited by
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
Sehn, L. H., & Salles, G. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2027612 · Cited by 1,175
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Böltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simon, D., Kleyer, A., Munoz, L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,092
Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00662-6 · Cited by 799
Self-citationGlofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206913 · Cited by 761
Metadata
- Authors
- Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., Solomon, S. R., Ghosh, N., Albertson, T. M., Garcia, J., Kostic, A., Mallaney, M., Ogasawara, K., Newhall, K., Kim, Y., Li, D., & Siddiqi, T.
- Affiliations
- Massachusetts General Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Northwestern University (US)
- University of Nebraska Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Beth Israel Deaconess Medical Center (US)
- University of Alabama at Birmingham (US)
- University of Colorado Anschutz (US)
- Fred Hutch Cancer Center (US)
- University of California, San Francisco (US)
- UPMC Hillman Cancer Center (US)
- Northside Hospital (US)
- Levine Cancer Institute (US)
- Bristol-Myers Squibb (United States) (US)
- City Of Hope National Medical Center (US)
- Corresponding author
- Abramson, Jeremy S
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 396
- Issue
- 10254
- Pages
- 839-852
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3082855561
- Cited by
- 2,430
- References
- 40
- Citations by year
- 2026: 299 · 2025: 419 · 2024: 481 · 2023: 444 · 2022: 479 · 2021: 288 · 2020: 16
- FWCI
- 110.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- lisocabtagene maraleucel, CAR T-cell therapy, large B-cell lymphoma, relapsed/refractory lymphoma, CD19, diffuse large B-cell lymphoma, double-hit lymphoma, triple-hit lymphoma, primary mediastinal B-cell lymphoma, objective response rate, dose-limiting toxicity, neurotoxicity
- MeSH terms
- Cytokine Release Syndrome, Aged, Aged, 80 and over, Anemia, Biological Products, Female, Humans, Infusions, Intravenous, Leukapheresis, Male, Nervous System Diseases, Neutropenia, Recurrence, Safety, Thrombocytopenia, CD4-Positive T-Lymphocytes, Survival Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Treatment Outcome, CD8-Positive T-Lymphocytes, Antigens, CD19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. https://app.cochat.ai/papers/10.1016/s0140-6736(20)31366-0
- The paper
- Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., Solomon, S. R., Ghosh, N., Albertson, T. M., Garcia, J., Kostic, A., Mallaney, M., Ogasawara, K., Newhall, K., . . . Siddiqi, T. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. https://doi.org/10.1016/s0140-6736(20)31366-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.